Participant flow

Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation · Source last updated 2026-09-03

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Participants in this dose-escalation cohort self-administered enasidenib mesylate orally at a dose of 100 mg once daily.

   id

   FG000

   title

   Enasidenib Mesylat 100mg

2. description

   Participants in this dose-escalation cohort self-administered enasidenib mesylate orally at a dose of 200 mg once daily.

   id

   FG001

   title

   Enasidenib Mesylat 200mg

periods

1. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         3

      2. group Id

         FG001

         num Subjects

         14

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         2

      2. group Id

         FG001

         num Subjects

         8

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         1

      2. group Id

         FG001

         num Subjects

         6

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice